RecruitingPhase 3NCT06044077

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Aged 2 Years and Above

Sponsor

Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Enrollment

1,920 participants

Start Date

Sep 8, 2023

Study Type

INTERVENTIONAL

Conditions

Pneumococcal disease

Summary

This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called 23-valent pneumococcal polysaccharide vaccine and a biological treatment called control pneumococcal polysaccharide vaccine for people with pneumococcal disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.